Browse the latest forensic toxicology articles or search the collection.
-
Methamphetamine-Associated Psychosis: Similar Symptom Scores Did Not Mean Similar Treatment Retention
A small inpatient comparison found similar psychosis-score improvement but different retention and adverse-event patterns. Early termination, partial blinding and a dosing inconsistency limit interpretation.
-
Aripiprazole and Methamphetamine Use: Falling Urine Positivity in Both Arms Did Not Establish a Medication Benefit
A 90-person placebo-controlled trial found no significant aripiprazole advantage despite declining urine positivity in both groups. Changing visit denominators and adherence measures help define what the result supports.
-
Buprenorphine Versus Bupropion for Methamphetamine Craving: Why 69 Randomized Became 65 Analyzed
A 14-day inpatient comparison reported lower craving with buprenorphine, but four bupropion-assigned patients refused medication before treatment. The selected analysis and absence of placebo limit wider efficacy claims.
-
Methylphenidate for Methamphetamine Use: Final-Month Days and Change From Baseline Answered Different Questions
A 110-person trial found a null primary final-month comparison and a favorable secondary change-from-baseline result. The outcome definition must remain attached to each conclusion.
-
Bupropion and False-Positive Amphetamine Screens: Why 41% Was Not the Risk for Every Patient
A historical hospital study found recorded bupropion use in 53 of 128 unconfirmed amphetamine screens. That conditional proportion did not measure the probability that any person taking bupropion would screen positive.
-
Does an Amphetamine-Positive Screen Explain a High White-Cell Count? Reading 1,206 Emergency Visits
A retrospective emergency-department study associated amphetamine-class urine positivity with higher white-cell counts. The class screen, selected population and unmeasured medication history prevented a drug-specific causal diagnosis.
-
Can an OPRM1 Variant Select Naltrexone Treatment for Methamphetamine Dependence? A 22-Person Pilot
A prospective genotype-selected pilot found no significant difference between two small groups receiving injectable naltrexone. It did not validate a genetic treatment-selection test or provide a placebo comparison.
-
Ibudilast in a 125-Person Methamphetamine Trial: A Serum Drug Level Was Not Proof of Brain Target Engagement
A placebo-controlled outpatient trial found no end-of-treatment abstinence advantage from ibudilast. A single serum measurement confirmed exposure at one time, without establishing sustained adherence or an anti-inflammatory brain effect.
-
Oxytocin and Methamphetamine Group Therapy: Better Attendance Was a Different Outcome From Less Drug Use
A small human trial found higher session-attendance odds with intranasal oxytocin, without a corresponding methamphetamine-use benefit. The attendance model, cohort structure and selected analysis population matter.
-
Atomoxetine for Amphetamine-Type Stimulant Use: A Larger Adherence-Subgroup Effect Needed a Different Denominator
A Malaysian pilot trial reported a small overall urine-test effect estimate and a larger estimate among participants reporting greater medication adherence. The subgroup did not preserve the original randomized comparison.
-
Did Sustained-Release Dextroamphetamine Reduce Methamphetamine Use or Mainly Withdrawal and Craving?
An eight-week trial distinguished prescribed dextroamphetamine from methamphetamine in its testing and found lower withdrawal and craving scores without a significant methamphetamine-use reduction.
-
Perindopril During Methamphetamine Exposure: Less Reported Stimulation Did Not Establish Cardiovascular Protection
A 60-participant laboratory study found lower anxious and stimulated ratings at one perindopril dose. Cardiovascular comparisons and drug-by-treatment interactions did not establish corresponding protection.
-
Rivastigmine and Methamphetamine: Saying “Likely to Use” Was Different From Choosing an Infusion
A historical laboratory experiment found a change in one methamphetamine-related rating without fewer drug-infusion choices. Its selected 15-person analysis and choice procedure limit treatment conclusions.
-
Sertraline and Methamphetamine Craving: A Selected Reanalysis Was Not a Validated Prediction Tool
A historical reanalysis linked sustained craving with increased methamphetamine-positive urine proportions in selected sertraline-treated participants. Its data-derived threshold and small subgroup limit individual prediction and causal claims.
-
Lisdexamfetamine in Older Adults: Why an Age Pattern Did Not Make Creatinine Clearance Irrelevant
A 47-person single-dose study found modestly higher active amphetamine exposure in the oldest group without a baseline creatinine-clearance relationship. Its healthy-volunteer selection limits the renal and clinical conclusions.
-
Did Intensive Counseling Hide an Ondansetron Benefit for Methamphetamine Dependence?
An eight-week randomized trial found no methamphetamine-use advantage at three ondansetron doses. Its suggestion that intensive counseling obscured a benefit remained an untested explanation.
-
Topiramate and Methamphetamine Abstinence: Reading the Primary Result Before the Subgroup
A 140-adult trial did not show a significant primary abstinence benefit from topiramate. Favorable use-reduction measures and a 26-person baseline-negative subgroup require separate interpretation.
-
Viloxazine With Lisdexamfetamine: What a Single-Dose Interaction Study Left Untested
A healthy-adult crossover study met its prespecified exposure criteria for viloxazine and d-amphetamine. Its design did not test added ADHD benefit, chronic coadministration or an individual guarantee of safety.
-
Do Guanfacine and Lisdexamfetamine Cancel Each Other’s Cardiovascular Effects?
A historical crossover study found similar active amphetamine exposure with and without guanfacine. That result did not establish that the two medicines cancel each other’s effects on pulse or blood pressure.
-
The ARTEMIS Methamphetamine Trial: Lower HIV Viral Load Did Not Mean Every Stimulant Outcome Improved
A 110-man randomized trial found lower HIV viral load with a positive-affect intervention added to contingency management. Urine stimulant outcomes, craving and immune-cell counts did not all show corresponding significant differences.